Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma
about
Liver resection and transplantation in hepatocellular carcinomaNovel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and developmentPrognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospectsRole of epigenetic aberrations in the development and progression of human hepatocellular carcinomaGene expression profiling of liver cancer stem cells by RNA-sequencingIdentifying prognostic features by bottom-up approach and correlating to drug repositioningMiningABs: mining associated biomarkers across multi-connected gene expression datasetsAverage rank-based score to measure deregulation of molecular pathway gene setsComparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma.Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma.Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the LiverHERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma.Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotypeInactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies.Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma.HCC: current surgical treatment concepts.Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis.Human Hepatocellular Carcinomas with a Periportal Phenotype Have the Lowest Potential for Early Recurrence after Curative Resection.Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma.SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma.High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma.Liver transplantation: past, present and future.Clinical characteristics and survival of European patients with resectable large hepatocellular carcinomas.Integrated analysis of prognostic gene expression profiles from hepatitis B virus-positive hepatocellular carcinoma and adjacent liver tissue.Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis.An enhanced topologically significant directed random walk in cancer classification using gene expression datasets.Chronic liver injury promotes hepatocarcinoma cell seeding and growth, associated with infiltration by macrophages.Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
P2860
Q26823395-71FE2241-15B0-4976-B457-3705C099EDAAQ26851211-940D4A51-6325-47E3-A571-EE24BDD735D5Q27021265-67EC6BB1-DCA2-43E1-9ADC-F72CF1C189DCQ27023524-63FAF105-1D2C-4356-825C-4171517886FEQ28483663-8BE0CA0B-E0E0-4093-8A12-34A85AE8D918Q28543844-69208E1B-F936-4BA3-85B1-DA8A9C715008Q33799844-3146B6AA-950D-49B9-BA70-DFA06648727EQ34077968-CD44540A-9D3C-4AFB-9099-B2214C078AB8Q34168643-20A86CC0-06A5-46F3-9110-BD15DB260DE2Q35608091-4B2C023D-D485-4461-9613-4FE75A1FDDCFQ35613914-F921E288-86EF-49BB-A7BC-E532B4573666Q36157238-39440EE9-14D7-4E66-B6BA-020FF0991271Q36364376-DA6C6D6B-E7B0-48C2-840B-512C1E327ACBQ36922108-1603CE06-4500-49B0-8BFA-C6209F68FCF1Q37141152-5D9798AA-301F-4FB2-B8C9-3D8C114B3098Q37586808-CB4C8567-AC56-441F-AA77-120A2C5F0331Q37891167-CF2FE99D-FBC5-48AC-8269-102EE62BF330Q37980015-84CC8B75-9653-49D1-A9BF-1EC5CFD77A1CQ38207102-5BD0AA47-13DA-4D39-8E07-1407FCF92247Q38981016-CE441A11-D90D-47BF-BDC3-8C9D45753E42Q40148438-E407B676-8AE3-439F-B9D7-4F2927E165A9Q40149927-4AADC256-D795-4575-8A45-D209BB502753Q42366620-71B2F5D7-B0D4-4CEA-8252-5F2D39649004Q43080766-D07A82B5-6C73-4D28-BA70-8B55CCE80CB0Q44195675-5EC3C76C-5FA2-4893-A22D-94CC57555EBEQ44269246-A74C1308-B782-4F94-9EE3-DD10F5F22D7DQ45366925-0334047E-5AD5-4D08-95F2-1EB94CDE4370Q45958504-B2BA5495-3640-43E5-B881-AF1C878FFBD7Q52351202-BDF04B8A-5748-4E5D-A9DE-6539F2F993D4Q55518185-0F591C1B-AC34-4539-9BE3-C9FB4BF2AEECQ56891008-DF0E8EA2-24C8-41F3-9517-DA728FC954CD
P2860
Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Gene expression in nontumoral ...... itive hepatocellular carcinoma
@ast
Gene expression in nontumoral ...... itive hepatocellular carcinoma
@en
type
label
Gene expression in nontumoral ...... itive hepatocellular carcinoma
@ast
Gene expression in nontumoral ...... itive hepatocellular carcinoma
@en
prefLabel
Gene expression in nontumoral ...... itive hepatocellular carcinoma
@ast
Gene expression in nontumoral ...... itive hepatocellular carcinoma
@en
P2093
P2860
P356
P1433
P1476
Gene expression in nontumoral ...... itive hepatocellular carcinoma
@en
P2093
Hideki Fujii
Hiroshi Kono
Ivan Rusyn
Joel S Parker
Masanori Matsuda
Masato Tsuchiya
P2860
P2888
P356
10.1186/1476-4598-9-74
P577
2010-04-09T00:00:00Z
P5875
P6179
1000899714